chronic myelocytic leukemia
Conditions
Interventions
Peg IFN a-2b combined TKI treatment group:None
Sponsors
The West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Participants with chronic phase CML with no other concurrent tumors; 2. Participants who have not achieved MMR with TKI treatment >= 1 year or Patients who have not achieved stable DMR withTKI treatment >= 2 years; 3. Age between 18 to 70 years old; 4. ECOG score =1.5*10^9 / L and platelet (PLT)>=80*10^9 / L ; 8. Subjects voluntarily signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergy to active ingredients, a -interferon or any excipients of this product; 2. Uncontrolled diabetes mellitus, hypertension, thyroid disease, retinopathy, autoimmune diseases, etc; 3. Severe liver dysfunction or decompensated liver cirrhosis; 4. A history of severe heart disease, including unstable or uncontrolled heart disease within 6 months; 5. A history of serious mental illness or serious mental illness, mainly of which are depression; 6. Pregnant women or women of childbearing potential and lactation women, or men of childbearing potential; 7. Severe kidney disease (undergoing hemodialysis), epilepsy (requiring antispasticity therapy); 8. A history of other malignancies within three years; 9. Patients with HAV, HCV, HDV, HEV infection, and autoimmune liver disease; 10. Not suitable for participating in this clinical trial judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DMR%;MMR%; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety during combination therapy;Maintenance of DMR after stopping PEG-IFN a; | — |
Countries
China
Contacts
Public ContactYunfan Yang
The West China Hospital of Sichuan University
Outcome results
None listed